Related Experiment Video
Updated: Jul 8, 2026
08:13
An Antibody Feeding Approach to Study Glutamate Receptor Trafficking in Dissociated Primary Hippocampal Cultures
Published on: August 2, 2019
Glutamatergic dysfunction--newer targets for anti-obsessional drugs
Sagnik Bhattacharyya1, Koushik Chakraborty
1Section of Neuroimaging, Box 67, Division of Psychological Medicine, Institute of Psychiatry, King's College London, SE5 8AF, UK. s.bhattacharyya@iop.kcl.ac.uk
Recent Patents on CNS Drug Discovery
|January 29, 2008
Summary
Many patients with obsessive compulsive disorder (OCD) do not respond to standard treatments. Glutamate-modulating drugs show promise as an alternative therapy for OCD, with recent patents emerging for novel compounds.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Obsessive compulsive disorder (OCD) affects a significant portion of the population.
- Current treatments, including serotonin reuptake inhibitors (SRIs) and cognitive behavioral therapy (CBT), are ineffective for 40-60% of patients.
- A substantial number of individuals with OCD remain symptomatic despite combined pharmacotherapy and CBT.
Purpose of the Study:
- To explore the rationale behind targeting glutamatergic agents for OCD treatment.
- To review recent patents for novel compounds aimed at modulating glutamate pathways in OCD.
- To highlight glutamate dysfunction as a potential therapeutic target for OCD.
Main Methods:
- Review of scientific literature on glutamatergic dysfunction in OCD.
- Analysis of recent patent filings for glutamate-modulating compounds.
- Focus on the underlying mechanisms and therapeutic potential of targeting the glutamate system.
Main Results:
- Evidence suggests a link between glutamatergic dysfunction and OCD pathophysiology.
- Glutamate-modulating drugs represent a promising alternative pharmacological strategy for OCD.
- Recent patents indicate active development of novel compounds targeting the glutamate system for OCD.
Conclusions:
- Glutamatergic dysfunction is implicated in the development of OCD.
- Targeting the glutamate system offers a potential new avenue for treating refractory OCD.
- Further research and development of glutamate-modulating agents are warranted for OCD treatment.
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...